CryoCath Surgifrost
This article was originally published in The Gray Sheet
Executive Summary
Surgical cryoablation system will debut in July following recent 510(k) clearance received by strategic partner Endocare for treatment of cardiac arrhythmias in patients undergoing other cardiac procedures such as bypass surgery and valve replacement. The firm sees a $200 mil. market opportunity...
You may also be interested in...
CryoCath Looks To Ice Atrial Fibrillation, Flutter With Cryoablation Therapies
CryoCath aims to place its Freezor cryoablation catheter in 300 centers by year-end, pending PMA approval of the supraventricular tachycardia treatment device
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.